Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284352 | 0.79 | BRPF1 (0.68) | DAOMCL1BRPF1MEN1MAPT | |
| SCHEMBL29152453 | 0.79 | MCL1 (0.42) | DAOMCL1MEN1HTTKMT2A | |
| SCHEMBL1238984 | 0.77 | DAO (1.00) | DAOMCL1BRPF1MEN1MAPT | |
| SCHEMBL20284504 | 0.74 | CYP19A1 (0.56) | DAOMEN1MAPTHTTKMT2A | |
| SCHEMBL21812440 | 0.74 | MCL1 (0.58) | MCL1BRPF1MEN1MAPTRAB9A | |
| SCHEMBL29209042 | 0.74 | THRB (0.47) | MCL1EGLN1MEN1MAPTHTT | |
| SCHEMBL21848211 | 0.73 | DAO (0.50) | DAOMCL1BRPF1 | |
| SCHEMBL2172818 | 0.73 | BRPF1 (0.62) | MCL1BRPF1 | |
| SCHEMBL16440985 | 0.72 | MCL1 (0.76) | MCL1 | |
| SCHEMBL418126 | 0.72 | MCL1 (1.00) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3728232-B1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-08-30 | — | — | EP | disclosed |
| EP-3728232-B1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-08-30 | — | — | EP | disclosed |
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-11192880-B2 | Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-12-07 | — | — | US | disclosed |
| US-11192880-B2 | Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-12-07 | — | — | US | disclosed |
| US-11091460-B2 | Syk inhibitor and use method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-110678461-B | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20200325119-A1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-15 | — | — | US | disclosed |
| US-20200325119-A1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-15 | — | — | US | disclosed |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| CN-110678461-A | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091460-B2 | Syk inhibitor and use method therefor | SYK, BTK, LCK | DAO 3906/4885MCL1 461/4885BRPF1 1385/4885 |
| US-11192880-B2 | Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders | BCL6, BCL6B, BCOR | DAO 3668/4885MCL1 27/4885BRPF1 346/4885 |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | SYK, BTK, LCK | DAO 3906/4885MCL1 461/4885BRPF1 1385/4885 |
| US-20200325119-A1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | BCL6, BCL6B, BCOR | DAO 3779/4885MCL1 32/4885BRPF1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.